Every 10-Q that Biote Corp. (BTMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BTMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BTMD filings page.
biote Corp. reported weaker results for the three months ended June 30, 2026. Total revenue was $44,232 thousand, down from $48,863 thousand a year earlier, as pellet procedure revenue declined while dietary supplement revenue grew modestly. Selling, general and administrative expense rose to $32,426 thousand from $24,223 thousand, including $5,100 thousand of charges tied to legal settlements and other resolved matters. Income from operations swung to a loss of $3,508 thousand compared with income of $10,765 thousand in 2025. Net loss attributable to stockholders was $6,563 thousand versus net income of $3,185 thousand, or basic and diluted loss per share of $0.23.
For the six months ended June 30, 2026, revenue was $89,167 thousand versus $97,855 thousand and net loss attributable to stockholders was $4,286 thousand versus net income of $16,903 thousand. Cash and cash equivalents declined to $11,168 thousand from $24,123 thousand at December 31, 2025, as net cash provided by operating activities fell to $2,726 thousand and the company used cash for share repurchases and settlement of a prior share repurchase liability. In May 2026, biote entered an amended and restated credit agreement providing a $125,000 thousand term loan and $50,000 thousand revolving facility maturing in 2031; term loan principal outstanding was $125,000 thousand at June 30, 2026. Total liabilities were $159,891 thousand and stockholders’ deficit was $58,192 thousand. All amounts are in thousands.
biote Corp. reported weaker Q1 2026 results as a product recall and higher costs weighed on performance. Total revenue was $44.9 million, down from $49.0 million a year earlier, as pellet procedure revenue declined while dietary supplement sales grew.
Net income attributable to stockholders fell to $2.3 million from $13.7 million, or $0.06 diluted earnings per share versus $0.37. Management estimates the January 2026 voluntary recall of certain hormone pellets reduced pellet procedure revenue by about $1.7 million and added roughly $1.5 million of recall-related costs in the quarter.
Cash and cash equivalents dropped to $5.3 million from $24.1 million at year-end, largely reflecting an $18.5 million payment to settle share repurchase liabilities, $1.1 million of Class A share buybacks and term-loan repayments. Long-term debt includes a $101.6 million term loan and $5.0 million drawn on the revolving facility, and the company remains in a stockholders’ deficit position despite modest profit and $8.7 million of Adjusted EBITDA.
biote Corp. (BTMD) reported Q3 2025 results showing lower sales but continued profitability. Total revenue was $47.96M, down from $51.38M a year ago, as product revenue softened. Income from operations was $8.27M versus $12.18M last year. Net income attributable to stockholders was $8.19M, or diluted EPS of $0.22, compared with $0.33 a year ago.
For the first nine months of 2025, revenue totaled $145.81M and net income attributable to stockholders was $25.09M. Operating cash flow for the period was $27.63M, illustrating solid cash generation. Cash and equivalents were $28.05M, with a term loan balance of $104.69M and $50.0M available under the revolving credit facility.
The company reduced obligations tied to prior settlements: share repurchase liabilities were $40.46M (current and long-term combined) at quarter end, aided by a September amendment to repurchase 2.8M Class V shares for $12.5M, which was paid on October 6, 2025. The fair value of earnout liabilities declined to $5.36M from $17.24M, contributing to other income.
biote Corp. (BTMD) reported a return to profitability for the quarter ended June 30, 2025 while carrying meaningful leverage and ongoing contingent liabilities. Total revenue for the quarter was $48.9 million (product revenue $47.7M), roughly flat year-over-year, and operating income improved to $10.8 million from $6.2M a year earlier. Net income for the quarter was $3.9 million and net income attributable to Biote stockholders was $3.2 million (basic EPS $0.10), reversing prior-year losses. For the six months, net income was $19.8 million and revenue totaled $97.9 million.
On the balance sheet, cash declined to $19.6 million from $39.3M at year-end and total assets fell to $104.8 million. Total liabilities remained elevated at $183.6 million, leaving a stockholders' deficit attributable to Biote of $85.1 million. The company remains in compliance with its credit covenants on a Term Loan that matures in May 2027. Significant items in the period include a $8.9 million mark-to-market gain on earnout liabilities and settlement activity that reduced share repurchase liabilities following a $25.1M repurchase payment.